Cosmos Health Announces Successful EN 12791 Study Results for C-Scrub Wash 4%, Strengthening Expansion into Hospital and Surgical Markets
Rhea-AI Summary
Cosmos Health (NASDAQ:COSM) announced that C-Scrub Wash 4%, made by subsidiary Cana Laboratories, successfully completed testing under EN 12791:2016+A1:2017, the European surgical hand disinfection standard. The independent QACS study confirmed effective antimicrobial activity for surgical hand antisepsis.
The company says this supports expansion into hospital, surgical, and institutional healthcare channels, strengthens the C-Scrub brand, and complements growing commercial availability in the United Kingdom.
Positive
- EN 12791 study successfully completed for C-Scrub Wash 4%
- Formulated with 4% Chlorhexidine Digluconate
- Supports entry into hospital and surgical channels
- Expanding commercial availability in the United Kingdom
Negative
- None.
News Market Reaction – COSM
In the Apr 1 session, COSM gained 0.60%, reflecting a mild positive market reaction. Argus tracked a peak move of +13.4% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Crypto Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 19 | Business update | Positive | -0.4% | Record revenue, U.S. expansion, high-margin NOOR Collagen projections and LOI acquisition. |
| Mar 11 | Crypto treasury move | Positive | +1.1% | Purchase of $600,000 in Bitcoin, lifting total digital assets to $3.1 million. |
| Feb 19 | Asset value highlight | Positive | -5.9% | Disclosure of $15M Athens real estate value exceeding market capitalization. |
| Feb 18 | C-Scrub retail expansion | Positive | +9.5% | C-Scrub Wash 4% rollout through Superdrug’s 830+ stores and pharmacies. |
| Feb 18 | C-Scrub retail expansion | Positive | +9.5% | C-Scrub Wash 4% added at Tesco, expanding UK retail footprint and visibility. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent COSM news with fundamentally positive tone has produced mixed reactions, with both aligned rallies and notable sell-offs following valuation and asset-focused updates.
Over the past months, Cosmos Health issued several value-focused and expansion updates, including record revenue, a planned acquisition generating €10 million (≈$11.5 million) in annual revenue, and highlighting $15 million in real estate value versus market cap. It also expanded C-Scrub distribution via Tesco and Superdrug in the UK and grew digital asset holdings to $3.1 million. Today’s EN 12791 validation for C-Scrub Wash 4% extends that product’s trajectory from retail and pharmacy channels toward hospital and surgical settings, reinforcing the infection-control portfolio narrative.
Key Terms
en 12791:2016+a1:2017 medical
surgical hand disinfection medical
chlorhexidine digluconate medical
antimicrobial medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHICAGO, IL / ACCESS Newswire / April 1, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that C-Scrub Wash
The independent study, conducted by Quality Assurance & Control Systems Ltd. (QACS), a Greece-based testing and certification laboratory specializing in microbiological and disinfectant efficacy studies, confirmed that C-Scrub Wash
EN 12791 is a widely recognized European benchmark for surgical hand antisepsis products and supports entry into hospital, surgical, and professional healthcare channels. The Company believes that successful completion of this study strengthens the clinical positioning of C-Scrub Wash
This milestone comes as C-Scrub continues gaining traction across several key markets, including the United Kingdom, where Cosmos Health has recently announced expanding commercial availability and growing market presence. The Company believes the EN 12791 study completion further supports its strategy to expand the C-Scrub portfolio across both retail and institutional healthcare channels.
The Company believes that this achievement further strengthens Cosmos Health's infection control portfolio, enhances the commercial positioning of the C-Scrub brand, and supports continued international growth.
Greg Siokas, CEO of Cosmos Health, stated: "The successful completion of the EN 12791 study for C-Scrub Wash
C-Scrub Wash
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans," and similar expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could," generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company's control, including, but not limited to: the Company's ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company's business, operations, and the economy in general; and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
SOURCE: Cosmos Health Inc.
View the original press release on ACCESS Newswire